Earlier this week, Neurocrine Biosciences reported new real-world clinician survey data showing that INGREZZA (valbenazine) improved uncontrolled movements and day-to-day functioning in adults with ...

Thanks to new regulatory frameworks like the Food and Drug Administration’s Breakthrough Therapy designation, drugs are coming to market faster than ever. A 2024 analysis of drugs included in this ...

Why INGREZZA data matters for Neurocrine Biosciences stock Neurocrine Biosciences (NBIX) has drawn fresh attention after presenting new real world clinician survey data on INGREZZA in mild tardive ...

The rise in direct-to-patient therapeutics access via online compounding pharmacies and other direct-to-patient sales models has increased the likelihood of patients utilizing medications alongside ...

Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...

Maribavir is an effective and well-tolerated option for cytomegalovirus infection and disease among hematopoietic cell ...

Discover how financial firms are leveraging synthetic data and AI to improve forecasting, risk modeling, and decision-making ...

Jeffrey Stark, MD, vice president, head of medical immunology, UCB, discusses ongoing clinical trials and the development of real-world data to understand the effectiveness of bimekizumab-bkzx in a ...

Today’s health care leaders are awash in data. There’s no shortage of organizations collecting, structuring, and licensing massive real-world data sets, each touting millions of de-identified “patient ...

Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone, are ...